Quetiapine Extended Release Depression Symptoms - Full Text View

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00640562

Purpose

Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Condition	Intervention	Phase
Schizophrenia Depression	Drug: Quetiapine Extended Release Drug: Risperidone	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone Int he Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study

Resource links provided by NLM:

MedlinePlus related topics: Depression Schizophrenia

Drug Information available for: Risperidone Quetiapine Quetiapine fumarate

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

To evaluate the efficacy of Seroquel XR™ versus Risperidone on depressive symptoms assess with Calgary Depression Scale of Schizophrenia (CDSS: Addington D etal 1990), in schizophrenic or schizoaffective patients [ Designated as safety issue: No ]

Secondary Outcome Measures:

To evaluate the efficacy of Seroquel XR™ versus Risperidone on depressive symptoms in schizophrenic or schizoaffective patients, assessed with Hamilton Rating Scale for Depression (HAM-D; Hamilton M 1960) [ Designated as safety issue: No ]
To evaluate efficacy of Seroquel XR™ vs. Risperidone on negative and positive symptoms, in schizophrenic and schizoaffective patients, assess with positive and negative Syndrome Scale (PANSS; Kay SR et al 1978) [ Designated as safety issue: No ]
To evaluate efficacy of Seroquel XR™ vs. Risperidone on attitude towards treatment in schizophrenic or schizoaffective patients, assess with Drug Attitude Inventory (DAI-10; Hogan TO et al, 1983) [ Designated as safety issue: No ]

Enrollment:	216
Study Start Date:	February 2008
Study Completion Date:	February 2010
Primary Completion Date:	February 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1	Drug: Quetiapine Extended Release Other Name: Seroquel XR™
Active Comparator: 2	Drug: Risperidone Other Name: Risperdal

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Provision of written informed consent
Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective disorder according to DSM-IVTR
Baseline depressive symptoms, assessed by means of HAM-D (21-item) score ≥20, and HAM-D item 1 score ≥2

Exclusion Criteria:

Any DSM-IV Axis I disorder other than schizophrenia and schizoaffective disorder
Patients treated with depot antipsychotic medications within 1 dosing interval before day 0; patients treated with other AP oral medications during the trial except for the switch period
Use of Clozapine within 28 days prior to enrollment or Clozapine non responders
Any significant clinical disorder that, in the opinion of the investigator, made the subject unsuitable to be given treatment with an investigational drug
An absolute neutrophil count (ANC) of ≤1.5 x 109 per liter
Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00640562

Locations

Italy
Research Site
Aosta, AO, Italy
Research Site
Fermo, AP, Italy
Research Site
Bergamo, BG, Italy
Research Site
Brindisi, BR, Italy
Research Site
Leno, BS, Italy
Research Site
Carbonia, CA, Italy
Research Site
Sanluri, CA, Italy
Research Site
Termoli, CB, Italy
Research Site
Aversa, CE, Italy
Research Site
Catania, CT, Italy
Research Site
Nicosia, EN, Italy
Research Site
Pontecorvo, FR, Italy
Research Site
Lido Di Camaiore, LU, Italy
Research Site
Messina, ME, Italy
Research Site
Milazzo, ME, Italy
Research Site
Monza, MI, Italy
Research Site
Nocera Inferiore, SA, Italy
Research Site
Vallo Della Lucania, SA, Italy
Research Site
La Spezia, SP, Italy
Research Site
Collegno, TO, Italy
Research Site
Frattaminore, Italy
Research Site
Lecco, Italy
Research Site
Palermo, Italy
Research Site
Partinico, Italy
Research Site
Roma, Italy

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Matteo Dionisi, MD	AstraZeneca
Principal Investigator:	Mario diFiorino	Ospedale Unico della Versilia (Lido di Camaiore, Lucca Italy)

More Information

No publications provided

Responsible Party:	Hans Eriksson, AstraZeneca
ClinicalTrials.gov Identifier:	NCT00640562 History of Changes
Other Study ID Numbers:	D1443L00031
Study First Received:	March 17, 2008
Last Updated:	February 17, 2010
Health Authority:	Italy: Ethics Committee

Keywords provided by AstraZeneca:

Schizophrenia
Depression
Quetiapine

Additional relevant MeSH terms:

Depression
Depressive Disorder
Schizophrenia
Behavioral Symptoms
Mood Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Risperidone
Quetiapine
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents

ClinicalTrials.gov processed this record on February 09, 2012